Patents Represented by Attorney, Agent or Law Firm Janet E. Hasak
-
Patent number: 4889818Abstract: A purified thermostable enzyme is obtained that has unique characteristics. Preferably the enzyme is isolated from the Thermus aquaticus species and has a molecular weight of about 86,000-90,000 daltons. The thermostable enzyme may be native or recombinant and may be used in a temperature-cycling chain reaction wherein at least one nucleic acid sequence is amplified in quantity from an existing sequence with the aid of selected primers and nucleotide triphosphates. The enzyme is preferably stored in a buffer of non-ionic detergents that lends stability to the enzyme.Type: GrantFiled: June 17, 1987Date of Patent: December 26, 1989Assignee: Cetus CorporationInventors: David H. Gelfand, Susanne Stoffel, Frances C. Lawyer, Randall K. Saiki
-
Patent number: 4886747Abstract: Nucleic acid encoding TGF-.beta. has been isolated and cloned into vectors which are replicated in bacteria and expressed in eukaryotic cells. TFG-.beta. is recovered from transformed cultures for use in known therapeutic modalities. Nucleic acid encoding TGF-.beta. is useful in diagnosis and identification of TGF-.beta. clones.Type: GrantFiled: March 13, 1987Date of Patent: December 12, 1989Assignee: Genentech, Inc.Inventors: Rik M. A. Derynck, David V. Goeddel
-
Patent number: 4879111Abstract: Infections in mammalian hosts may be treated therapeutically or prophylactically with an effective amount of at least one lymphokine before or after host infection, the amount being sufficient to achieve at least 50% protection of the host. Preferably, the lymphokine is IL-2 or a combination of TNF and IL-2 or TNF and IFN-.gamma.. Also, preferably the infection is bacterial and is being treated prophylactically. The combination of TNF and IL-2 or TNF and IFN-.gamma. is administered in synergistically effective amounts.Type: GrantFiled: April 17, 1986Date of Patent: November 7, 1989Assignee: Cetus CorporationInventor: Kong-Teck Chong
-
Patent number: 4863726Abstract: Anti-tumor activity in humans can be augmented by administering to the mammalian host a pharmacologically effective amount of mammalian IL-2 and at least one immunotoxin that binds selectively to human tumor cells. The IL-2 and immunotoxin are preferably administered separately to the host. The composition is useful for prophylactic or therapeutic treatment of such cancers as ovarian and breast cancer.Type: GrantFiled: December 9, 1987Date of Patent: September 5, 1989Assignee: Cetus CorporationInventors: Paul Stevens, L. L. Houston, Kirston E. Koths, Brian Issell, Robert Zimmerman
-
Patent number: 4863727Abstract: Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.Type: GrantFiled: November 16, 1988Date of Patent: September 5, 1989Assignee: Cetus CorporationInventors: Robert Zimmerman, Jeffrey L. Winkelhake
-
Patent number: 4835251Abstract: Production of human relaxin or novel human relaxin analogs by combination of a human relaxin A-chain and B-chain comprises combining the reduced form of the human relaxin A-chain and the reduced form of the human relaxin B-chain in an aqueous medium having a pH of about 7.0 to 12 at room temperature, under conditions that are mildly denaturing for the relaxin B-chain such that the human relaxin or novel human relaxin analog can be formed.Type: GrantFiled: June 23, 1986Date of Patent: May 30, 1989Assignee: Genetech, Inc.Inventors: John P. Burnier, Paul D. Johnston
-
Patent number: 4822731Abstract: Nucleic acids may be labeled by complexing the alkylating moiety of a labeling reagent into a single-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a single-stranded hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:[A--[B--Lwhere A is an alkylating moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the alkylating and label moieties.Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.Type: GrantFiled: January 9, 1986Date of Patent: April 18, 1989Assignee: Cetus CorporationInventors: Robert M. Watson, Edward L. Sheldon, III, Richard M. Snead
-
Patent number: 4816440Abstract: A pharmaceutical composition containing IL-2 or IFN-.beta. dissolved in a suitable carrier medium at pH 7.0 to 8.0 stabilized with sodium laurate is suitable for parenteral injection into humans or animals. This formulation may be prepared by adding to either protein, after its recovery from a transformed organism, an effective amount of sodium laurate at a pH of 9 to 9.5 and then adjusting the pH of the formulation to between 7.0 and 8.0.Type: GrantFiled: September 26, 1985Date of Patent: March 28, 1989Assignee: Cetus CorporationInventor: James W. Thomson
-
Patent number: 4803297Abstract: Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:[A--[B--Lwhere A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.Type: GrantFiled: July 13, 1987Date of Patent: February 7, 1989Assignee: Cetus CorporationInventors: Corey H. Levenson, Kary B. Mullis
-
Patent number: 4800159Abstract: The present invention is directed to a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof. The process comprises treating separate complementary strands of the nucleic acid with a molar excess of two oligonucleotide primers, extending the primers to form complementary primer extension products which act as templates for synthesizing the desired nucleic acid sequence, and detecting the sequence so amplified. The steps of the reaction may be carried out stepwise or simultaneously and can be repeated as often as desired.In addition, a specific nucleic acid sequence may be cloned into a vector by using primers to amplify the sequence, which contain restriction sites on their non-complementary ends, and a nucleic acid fragment may be prepared from an existing shorter fragment using the amplification process.Type: GrantFiled: December 17, 1986Date of Patent: January 24, 1989Assignee: Cetus CorporationInventors: Kary B. Mullis, Henry A. Erlich, Norman Arnheim, Glenn T. Horn, Randall K. Saiki, Stephen J. Scharf
-
Patent number: 4794175Abstract: A gene having a DNA sequence complementary to that of the glucoamylase polypeptide mRNA from a fungal species, preferably Aspergillus awamori, is prepared. The mRNA is an approximately 2.2 kilobase poly A RNA obtained from fungal cells grown under conditions of glucoamylase induction. Reverse transcription of the mRNA provides a glucoamylase probe used to identify genomic digest fragments containing glucoamylase gene regions, which are sequenced to locate the introns and exons. The genomic fragments are spliced together to form a gene having a DNA sequence with altered or deleted introns which codes for fungal glucoamylase protein and is capable, when correctly combined with a cleaved DNA expression vector, of expressing a non-native protein having glucoamylase enzyme activity upon transformation of a host organism by the vector. The host is preferably bacteria or yeast. The transformed yeast host may be used to produce ethanol.Type: GrantFiled: April 27, 1987Date of Patent: December 27, 1988Assignee: Cetus CorporationInventors: Jack Nunberg, Jeffrey E. Flatgaard, Michael A. Innis
-
Patent number: 4789630Abstract: Useful for visualizing biological materials in a solid phase, on a gel, or in a liquid phase is a solid salt of the meriquinone of benzidine or a substituted benzidine. An immobilized or dissolved complex of a polymeric anion and the meriquinone of benzidine or a substituted benzidine having controllable solubility may also be employed. Preferred are meriquinone salts and complexes of 3,3,5,5'-tetramethylbenzidine. For visualization, the benzidine or substituted benzidine is oxidized to its meriquinone at pH 3 to 7 in the presence of an effective anion or polymeric anion, an oxidation catalyst, and an effective amount of oxidant to form a solid salt or immobilized complex of the meriquinone under conditions where the meriquinone solubility lies below about 10.sup.-5 M.Type: GrantFiled: August 20, 1986Date of Patent: December 6, 1988Assignee: Cetus CorporationInventors: Will Bloch, Patrick J. Sheridan, Robert J. Goodson
-
Patent number: 4766106Abstract: A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.Type: GrantFiled: January 25, 1988Date of Patent: August 23, 1988Assignee: Cetus CorporationInventors: Nandini Katre, Michael J. Knauf
-
Patent number: 4758428Abstract: New multiclass hybrid interferon polypeptides, their corresponding encoding recombinant DNA molecules and transformed hosts which produce the new interferons are described. The amino acid sequences of these hybrids include at least two different subsequences, one of which has substantial homology with a portion of a first class of interferon (e.g., HuIFN-.alpha.) and the other which has substantial homology with a portion of a second class of interferon (e.g., HuIFN-.beta.). Data indicates the interferon activity of .alpha.-.beta. hybrids may be substantially restricted to either cell growth regulatory activity or antiviral activity.Type: GrantFiled: July 15, 1985Date of Patent: July 19, 1988Assignee: Cetus CorporationInventors: David F. Mark, Abla A. Creasey
-
Patent number: 4754065Abstract: Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:[A] [B] Lwhere A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.Type: GrantFiled: July 13, 1987Date of Patent: June 28, 1988Assignee: Cetus CorporationInventors: Corey H. Levenson, Kary B. Mullis
-
Patent number: 4752585Abstract: A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine T or peroxide oxidation, wherein additional, non-susceptible methionyl residues are not so substituted. The oxidation-resistant mutein so produced is preferably a human mutein of interleukin-2 or interferon-.beta., and the conservative amino acid is most preferably alanine.Type: GrantFiled: August 5, 1986Date of Patent: June 21, 1988Assignee: Cetus CorporationInventors: Kirston E. Koths, Robert F. Halenbeck, Michael A. Innis, Alice M. Wang, Ze'Ev Shaked
-
Patent number: 4751313Abstract: Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:[A][B]Lwhere A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moeity and L is biotin.Type: GrantFiled: July 13, 1987Date of Patent: June 14, 1988Assignee: Cetus CorporationInventors: Corey H. Levenson, Kary B. Mullis
-
Patent number: 4745180Abstract: A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is poorly or not at all water-soluble at pH 6-8 without such solubilizing agent, is selectively conjugated to at least one heparin fragment having a terminal 2,5-anhydro-D-mannose residue which has an aldehyde not involved in intramolecular hemiacetal formation.Type: GrantFiled: June 27, 1986Date of Patent: May 17, 1988Assignee: Cetus CorporationInventors: Margaret Moreland, Danute E. Nitecki
-
Patent number: 4727219Abstract: A method is disclosed for efficiently using genic male-sterile maize in hybrid seed production which allows economical maintenance of male-sterile stocks. This method enhances a natural linkage between a selected male-sterile gene and a marker gene conditioning an easily observable trait by deletion and screening to create stocks in which the linkage is effectively complete.Type: GrantFiled: November 28, 1986Date of Patent: February 23, 1988Assignee: AGRACETUSInventors: Gurdip S. Brar, Oliver Nelson
-
Patent number: H494Abstract: Serotype-specific murine anti-Pseudomonas monoclonal antibodies which bind to determinants of the cell wall lipopolysaccharides of P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.Type: GrantFiled: April 26, 1985Date of Patent: July 5, 1988Assignee: Cetus CorporationInventor: James W. Larrick